Wisconsin Alumni Research Foundation

Diagnostics & Biomarkers
Diagnostics Biomarkers
Early Detection of Hemangiosarcoma and Angiosarcoma
WARF: P05078US02

Inventors: Stuart Helfand, Jaime Modiano

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a simple, sensitive and specific test for detecting hemangiosarcoma in its early stages in dogs at risk.
Overview
Of the approximately 65 million domestic dogs in the United States, between 1.5 and 2.5 million will contract canine hemangiosarcoma, an incurable tumor of the cells that line blood vessels. Death usually results from acute internal hemorrhage following rupture of the tumor. Treatment is ineffective because the disease is diagnosed at a late stage when tumors are resistant to chemotherapy, and no method of early diagnosis currently exists.
The Invention
UW-Madison researchers have developed a simple, sensitive and specific test for detecting hemangiosarcoma in its early stages in dogs at risk. The inventors discovered that the “primitive” endothelial cells associated with hemangiosarcoma or angiosarcoma, a similar tumor that affects humans, express a specific combination of proteins on their surface. To diagnose hemangiosarcoma or angiosarcoma, multiparameter flow cytometry can be used to detect cells that express these proteins.
Applications
  • Early detction of hemangiosarcoma and related cancers
Key Benefits
  • Provides a method of detecting hemangiosarcoma at an early stage, when treatments may be more effective
  • Enables early diagnosis of angiosarcoma in people at high risk
  • Minimally invasive—diagnosis is made using a blood sample rather than a biopsy
  • Capable of distinguishing between hemangiosarcoma/angiosarcoma and benign proliferative lesions, such as hemangioma or hematoma
  • Can distinguish between hemangiosarcoma/angiosarcoma and leukemia/lymphoma, allowing treatments to be tailored to the particular disease
For current licensing status, please contact Jennifer Gottwald at [javascript protected email address] or 608-960-9854

WARF